Acro Announces Technology Agreement with LSRI (Life Science Research Israel)

New York, NY – September 26, 2007 – Acro, Inc. (OTC BB:ACRI), a developer of explosive detection solutions, today announced the conclusion of the negotiations of a technology agreement with LSRI – Life Science Research Israel Ltd., a subsidiary of IIBR – Israel Institute for Biological Research. Under the terms of the agreement, LSRI will license the long-proven technology of IIBR's explosives testing kit (ETK) to Acro, for incorporation into Acro's pen-like device, allowing the detection of commercial and military explosives. The agreement is subject to minimum annual revenues to be achieved by Acro and royalties to be paid to LSRI. The technical appendix of the agreement will be signed in the next few weeks. The new device will complement Acro's ACRO-P.E.T., the company’s peroxide explosive tester for the detection of improvised explosives. "The agreement with LSRI will allow Acro to provide unique, reliable and easy-to-use explosive testers for the entire spectrum of military, commercial and improvised explosives, using the company's patented pen-like tool," said Acro Chairman and CEO Gadi Aner. "This is an important milestone in Acro's evolution as a company offering a full array of explosive testers providing immediate detection in the field." IIBR's ETK is a portable micro-laboratory for rapid field detection of explosives. It is used by many security forces around the world. ACRO-P.E.T. is designed for rapid field detection of peroxide-based explosives, such as triacetone triperoxide (TATP). Its main advantages include high sensitivity, high selectivity, fast response, simple operation, small size and cost effectiveness. About LSRI - Life Science Research Israel Ltd. LSRI focuses on the commercialization of IIBR’s novel technologies and scientific achievements. Established in 1979, LSRI’s mandate is to promote biomedical projects and market IIBR-developed products and services. LSRI represents IIBR in the establishment of all forms of collaboration, joint ventures and partnerships with private and public companies. For more information about LSRI, visit www.iibr.gov.il/LSRI.asp About Acro, Inc. Acro, Inc. develops explosives detection technologies. The company has developed a unique patented technology forentifying peroxide-based explosives, such as TATP. Acro’s Advisory Board includes Prof. K. Barry Sharpless, winner of the 2001 Nobel Prize for Chemistry, and Prof. Richard A. Lerner, President and CEO of The Scripps Research Institute, considered one of the world’s most influential scientific institutes. For more information about Acro, visit www.acrosec.com. Forward Looking Statement This press release contains forward-looking statements concerning our marketing and operations plans. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. All forward-looking statements in this press release are made based on management's current expectations and estimates, which involve risks, uncertainties and other factors that could cause results to differ materially from those expressed in forward-looking statements. These statements involve a number of risks and uncertainties, including, but not limited to, risks related to the evolving homeland security market, our ability to successfully market and sell our TATP Explosive Tester product worldwide and ETK licensed from LSRI, the results of the technology  agreement with LSRI, our ability to satisfy the minimum  annual revenues set in the agreement with LSRI, and the ability to successfully demonstrate solutions to governmental national security agencies and national police forces, and additional orders from the US military, general economic conditions and other risk factors. Acro does not undertake any obligation to update forward-looking statements made herein. Media contact: David Kanaan Kanaan Public Relations Tel: +972-3-540-8188 E-mail:david@kanaan.co.il